Simultaneous approach for patients with synchronous colon and rectal liver metastases: Impact of site of primary on postoperative and oncological outcomes.


Journal

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
ISSN: 1532-2157
Titre abrégé: Eur J Surg Oncol
Pays: England
ID NLM: 8504356

Informations de publication

Date de publication:
04 2021
Historique:
received: 11 06 2020
revised: 02 09 2020
accepted: 15 09 2020
pubmed: 5 10 2020
medline: 28 9 2021
entrez: 4 10 2020
Statut: ppublish

Résumé

We aimed to investigate the impact of the site of the primary on postoperative and oncological outcomes in patients undergone simultaneous approach for colon (CC) and rectal cancer (RC) with synchronous liver metastases (SCRLM). Of the 220 patients with SCRLM operated on between Mar 2006 and Dec 2017, 169 patients (76.8%) were treated by a simultaneous approach and were included in the study. Two groups were considered according to the location of primary tumor RC-Group (n = 47) and CC-group (n = 122). Multiple liver metastases were observed in 70.2% in RC-Group and 77.0% in CC-Group (p = 0.233), whilst median Tumor Burden Score (TBS) was 4.7 in RC-Group and 5.4 CC-Group (p = 0.276). Severe morbidity (p = 0.315) and mortality at 90 days (p = 0.520) were comparable between RC-Group and CC-Group. The 5-year overall survival (OS) rate was similar comparing RC-Group and CC-Group (48.2% vs. 45.3%; p = 0.709), but it was significantly different when considering left-CC, right-CC and RC separately (54.5% vs. 35.2% vs. 48.2%; p = 0.041). Primary tumor location (right-CC, p = 0.001; RC, p = 0.002), microscopic residual (R1) disease at the primary (p < 0.001), TBS ≥6 (p = 0.012), bilobar metastases (p = 0.004), and chemotherapy strategy (preoperative ChT, p = 0.253; postoperative ChT, p = 0.012; and perioperative ChT, p < 0.001) resulted to be independent prognostic factors at multivariable analysis. In patients with SCRLM, simultaneous resection of the primary tumor and liver metastases seems feasible and safe and allows satisfactory oncological outcomes both in CC and RC. Right-CC shows a worse prognosis when compared to left-CC and RC.

Sections du résumé

BACKGROUND AND AIMS
We aimed to investigate the impact of the site of the primary on postoperative and oncological outcomes in patients undergone simultaneous approach for colon (CC) and rectal cancer (RC) with synchronous liver metastases (SCRLM).
PATIENTS AND METHODS
Of the 220 patients with SCRLM operated on between Mar 2006 and Dec 2017, 169 patients (76.8%) were treated by a simultaneous approach and were included in the study. Two groups were considered according to the location of primary tumor RC-Group (n = 47) and CC-group (n = 122).
RESULTS
Multiple liver metastases were observed in 70.2% in RC-Group and 77.0% in CC-Group (p = 0.233), whilst median Tumor Burden Score (TBS) was 4.7 in RC-Group and 5.4 CC-Group (p = 0.276). Severe morbidity (p = 0.315) and mortality at 90 days (p = 0.520) were comparable between RC-Group and CC-Group. The 5-year overall survival (OS) rate was similar comparing RC-Group and CC-Group (48.2% vs. 45.3%; p = 0.709), but it was significantly different when considering left-CC, right-CC and RC separately (54.5% vs. 35.2% vs. 48.2%; p = 0.041). Primary tumor location (right-CC, p = 0.001; RC, p = 0.002), microscopic residual (R1) disease at the primary (p < 0.001), TBS ≥6 (p = 0.012), bilobar metastases (p = 0.004), and chemotherapy strategy (preoperative ChT, p = 0.253; postoperative ChT, p = 0.012; and perioperative ChT, p < 0.001) resulted to be independent prognostic factors at multivariable analysis.
CONCLUSION
In patients with SCRLM, simultaneous resection of the primary tumor and liver metastases seems feasible and safe and allows satisfactory oncological outcomes both in CC and RC. Right-CC shows a worse prognosis when compared to left-CC and RC.

Identifiants

pubmed: 33011004
pii: S0748-7983(20)30786-1
doi: 10.1016/j.ejso.2020.09.015
pii:
doi:

Substances chimiques

Antineoplastic Agents 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

842-849

Informations de copyright

Copyright © 2020 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Simone Conci (S)

Department of Surgery, General and Hepatobiliary Surgery, University of Verona, University Hospital G.B. Rossi, 37134, Verona, Italy. Electronic address: simone.conci@aovr.veneto.it.

Andrea Ruzzenente (A)

Department of Surgery, General and Hepatobiliary Surgery, University of Verona, University Hospital G.B. Rossi, 37134, Verona, Italy.

Corrado Pedrazzani (C)

Department of Surgery, General and Hepatobiliary Surgery, University of Verona, University Hospital G.B. Rossi, 37134, Verona, Italy.

Giulia Isa (G)

Department of Surgery, General and Hepatobiliary Surgery, University of Verona, University Hospital G.B. Rossi, 37134, Verona, Italy.

Giulia Turri (G)

Department of Surgery, General and Hepatobiliary Surgery, University of Verona, University Hospital G.B. Rossi, 37134, Verona, Italy.

Tommaso Campagnaro (T)

Department of Surgery, General and Hepatobiliary Surgery, University of Verona, University Hospital G.B. Rossi, 37134, Verona, Italy.

Alessandro Valdegamberi (A)

Department of Surgery, General and Hepatobiliary Surgery, University of Verona, University Hospital G.B. Rossi, 37134, Verona, Italy.

Fabio Bagante (F)

Department of Surgery, General and Hepatobiliary Surgery, University of Verona, University Hospital G.B. Rossi, 37134, Verona, Italy.

Ivan Marchitelli (I)

Department of Surgery, General and Hepatobiliary Surgery, University of Verona, University Hospital G.B. Rossi, 37134, Verona, Italy.

Alfredo Guglielmi (A)

Department of Surgery, General and Hepatobiliary Surgery, University of Verona, University Hospital G.B. Rossi, 37134, Verona, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH